Kestra Medical Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue grew 63% year-over-year to $24.6M, with gross margin up to 52.6% and strong prescription growth. Fiscal 2026 revenue guidance was raised to $93M, and recent payer wins in Florida and the VA are expected to drive further growth and margin expansion.
-
Kestra is rapidly expanding in an underserved $10B U.S. market, driven by strong clinical results, high patient compliance, and a scalable rental model. Recent innovations, including a partnership with Biobeat for blood pressure monitoring, and robust insurance coverage support continued double-digit growth.
-
Q2 FY26 saw 53% revenue growth and gross margin surpassing 50% for the first time, driven by strong prescription volume, market expansion, and improved in-network mix. Updated guidance raises FY26 revenue to $91M, with continued investments in commercial expansion and clinical evidence supporting further growth.
-
Revenue grew 52% year over year to $19.4 million, with gross margin expanding to 45.7% and prescription volume up 51%. Fiscal 2026 revenue guidance was raised to $88 million, reflecting strong commercial execution and ongoing market share gains. Clinical milestones and improved payer mix support continued growth.
Fiscal Year 2025
-
A landmark post-approval study has strengthened clinical and competitive positioning, with new data expected to drive market share gains and potentially influence clinical guidelines. Operational execution remains strong, with scalable sales expansion and ongoing innovation supporting future growth.
-
Q4 and fiscal 2025 saw robust revenue and margin growth, driven by higher prescriptions, market share gains, and operational leverage. Fiscal 2026 guidance anticipates continued strong growth, with investments in commercial expansion and innovation supported by a solid cash position.
-
A newly public company is rapidly expanding in the wearable defibrillator market, leveraging a differentiated product with low false alarm rates and strong clinical support. With significant sales force growth, improved gross margins, and a major clinical study nearing completion, substantial revenue and market penetration gains are expected.
-
A rapidly growing med tech company is expanding its sales force and market coverage following a recent IPO, targeting a $10B U.S. market with a differentiated wearable defibrillator. Gross margins have improved significantly, and the company expects strong profitability as it scales, while continuing to invest in innovation.
-
Q3 FY2025 revenue grew 82% year-over-year to $15.1 million, driven by strong prescription growth and expanding market share. Gross margin improved to 43.4%, and FY2025 revenue is projected at $58–$58.5 million, up 109%–110% from FY2024.